Inclusion Criteria:  Patients voluntarily entered the study and signed informed consent form (ICF); Age: Be at least 18 years old and and there is no limit on the gender; Clinically or histologically diagnosed as unresectable HCC; There is at least one measurable lesions that meet the mRECIST standard; Child-pugh classification A or B (score≤7); The maximum number of TACE procedures allowed before enrolment was 2. All of those patients who had a history of prior TACE achieved complete response by previous TACE, but recurred more than 6 months later at the study entry ECOG : 0 ~ 2 ; Before the patients were enrolled in the study, doctors had decided to treat them with donafenib in combination with TACE.  Exclusion Criteria:  Donafenib forbidden population:  Those who are allergic to any component of the medicine; Active bleeding; Active peptic ulcer; Hypertension not controlled by drugs; Those with severe liver insufficiency. Medical conditions that affect absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.); Patients with a clear past history of neurological or psychiatric disorders; The patient had been treated with another study drug or study device in the 4 weeks prior to initial dosing; Pregnant or breastfeeding women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures; Unable to follow the research protocol for treatment or scheduled follow-up; Any other researcher who thinks they cannot be included.